Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Am J Hematol

Retrieve available abstracts of 145 articles:
HTML format

Single Articles

    July 2021
  1. KHURANA A, Hathcock M, Habermann TM, Al Saleh A, et al
    Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26293.

  2. CASTILLO JJ, Lamacchia J, Silver J, Flynn CA, et al
    Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26291.

  3. MEHTA-SHAH N, Lunning MA, Moskowitz AJ, Boruchov AM, et al
    Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts.
    Am J Hematol. 2021 Jul 12. doi: 10.1002/ajh.26288.
    PubMed     Abstract available

  4. VAUGHN JL, Spies D, Xavier AC, Epperla N, et al
    Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States.
    Am J Hematol. 2021;96:816-822.
    PubMed     Abstract available

    June 2021
  5. SARKOZY C, Michot JM, Quivoron C, Camara-Clayette V, et al
    Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26280.

  6. DEFRANCESCO I, Visentini M, Zibellini S, Minafo YA, et al
    Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
    Am J Hematol. 2021;96:E210-E214.

    May 2021
  7. MARTINEZ-CALLE N, Wilson MR, Eyre TA, Cwynarski K, et al
    Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in Diffuse Large B-cell Lymphoma; caution required.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26257.

  8. PUCKRIN R, Stewart DA
    Prophylactic high-dose methotrexate in diffuse large B cell lymphoma, authors' response.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26256.

  9. KHURANA A, Dalland J, Young JR, Inwards DJ, et al
    Brexucabtagene Autoleucel Therapy Induces Complete Remission in a Primary Refractory Blastoid Mantle Cell Lymphoma with Neurolymphomatosis.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26233.

  10. BODDICKER NJ, Larson MC, Castellino A, Herrmann J, et al
    Anthracycline Treatment, Cardiovascular Risk Factors and the Cumulative Incidence of Cardiovascular Disease in a Cohort of Newly Diagnosed Lymphoma Patients from the Modern Treatment Era.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26230.
    PubMed     Abstract available

    April 2021
  11. DULERY R, Lamure S, Delord M, Di Blasi R, et al
    Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.
    Am J Hematol. 2021 Apr 28. doi: 10.1002/ajh.26209.
    PubMed     Abstract available

  12. WALTER LP, Couronne L, Jais JP, Nguyen PD, et al
    Outcome after Haematopoietic Stem Cell Transplantation in Patients with Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: a French Study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26200.
    PubMed     Abstract available

  13. LAM M, Touitou V, Choquet S, Cassoux N, et al
    Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26199.
    PubMed     Abstract available

  14. PUCKRIN R, El Darsa H, Ghosh S, Peters A, et al
    Ineffectiveness of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2021 Apr 3. doi: 10.1002/ajh.26181.
    PubMed     Abstract available

  15. NAGLE SJ, Murphree C, Raess PW, Schachter L, et al
    Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    Am J Hematol. 2021;96:455-461.
    PubMed     Abstract available

    March 2021
  16. ALDERUCCIO JP, Saul EE, Iyer SG, Reis IM, et al
    R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - long term follow up results.
    Am J Hematol. 2021 Mar 18. doi: 10.1002/ajh.26163.
    PubMed     Abstract available

  17. QUINN D, Farrell K, Leach M, Bain BJ, et al
    An aggressive NK-cell lymphoma with hemophagocytosis.
    Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26154.

  18. MAURER MJ, Jakobsen LH, Mwangi R, Schmitz N, et al
    R/R International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
    Am J Hematol. 2021 Mar 4. doi: 10.1002/ajh.26149.
    PubMed     Abstract available

    2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
    Am J Hematol. 2021 Mar 4. doi: 10.1002/ajh.26151.
    PubMed     Abstract available

  20. HIGGINS A, Kim H, Harper L, Habermann TM, et al
    Testicular FDG-PET/CT uptake threshold in aggressive lymphomas.
    Am J Hematol. 2021;96:E81-E83.

  21. LAUDE MC, Lebras L, Sesques P, Ghesquieres H, et al
    First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.
    Am J Hematol. 2021;96:302-311.
    PubMed     Abstract available

    February 2021
  22. MORITA K, Jain N, Kantarjian H, Takahashi K, et al
    Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
    PubMed     Abstract available

    January 2021
  23. JAIN P, Kanagal-Shamanna R, Zhang S, Ok CY, et al
    Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
    Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26109.

  24. VAUGHN JL, Pinheiro LC, Olszewski A, Epperla N, et al
    Survival of Patients with Marginal Zone Lymphoma in the United States: A Population-Based Cohort Study (2000 to 2017).
    Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26103.

    October 2020
  25. TOBIN JW, Gandhi MK
    Risk-Adapted Therapy in Follicular Lymphoma: Is it time to FLEX?
    Am J Hematol. 2020 Oct 8. doi: 10.1002/ajh.26016.

  26. Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
    Am J Hematol. 2020;95 Suppl 1:S3-S38.

    September 2020
  27. NGUYEN MN, Nayernama A, Jones SC, Kanapuru B, et al
    Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
    Am J Hematol. 2020;95:E218-E222.

    August 2020
  28. LUO DX, Li W, Ye MT, Yang Y, et al
    "Double Hit" Anaplastic Large Cell Lymphoma with Concurrent ALK and MYC Rearrangements.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25980.

  29. BEIN J, Thurner L, Hansmann ML, Hartmann S, et al
    Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse.
    Am J Hematol. 2020 Aug 20. doi: 10.1002/ajh.25972.
    PubMed     Abstract available

  30. MIR F, Mattiello F, Grigg A, Herold M, et al
    Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Am J Hematol. 2020 Aug 20. doi: 10.1002/ajh.25973.
    PubMed     Abstract available

  31. BOSSI E, Aroldi A, Brioschi FA, Steidl C, et al
    Phase II study of crizotinib in patients with Anaplastic Lymphoma Kinase (ALK) positive Anaplastic Large Cell Lymphoma relapsed/refractory to chemotherapy.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25967.

  32. CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
    Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
    PubMed     Abstract available

  33. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Survival Analysis in Treated Plasmablastic Lymphoma Patients: a Population-based Study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25955.
    PubMed     Abstract available

  34. SESQUES P, Ferrant E, Safar V, Wallet F, et al
    Use of Commercial anti-CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center.
    Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25951.
    PubMed     Abstract available

    July 2020
  35. AMINI RM, Ljungstrom V, Abdulla M, Cavelier L, et al
    Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome.
    Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25927.

    June 2020
  36. SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
    Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.

    May 2020
  37. QI SN, Yang Y, Zhang YJ, Huang HQ, et al
    Risk-based, Response-adapted Therapy for Early-stage Extranodal Nasal-type NK/T-cell Lymphoma in the Modern Chemotherapy Era: A China Lymphoma Collaborative Group (CLCG) Study.
    Am J Hematol. 2020 May 25. doi: 10.1002/ajh.25878.
    PubMed     Abstract available

  38. MONDELLO P, Musolino C, Dogliotti I, Bohn JP, et al
    ABVD vs BEACOPP escalated in Advanced-Stage Hodgkin's Lymphoma: results from a multicenter European study.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871.
    PubMed     Abstract available

    Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2020 May 8. doi: 10.1002/ajh.25856.
    PubMed     Abstract available

  40. JAIN P, Tang G, Li S, Wang M, et al
    "Triple Hit" SOX-11(-) , CD10(+) , TP53 mutated high-grade pleomorphic mantle cell lymphoma.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25848.

    April 2020
  41. DHARMAVARAM G, Cao S, Sundaram S, Ayyapan S, et al
    Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25837.
    PubMed     Abstract available

  42. CHOW VA, Rajendran JG, Fisher DR, Appelbaum FR, et al
    A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25818.
    PubMed     Abstract available

  43. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.

  44. ZHAO S, Kanagal-Shamanna R, Navsaria L, Chi Young OK, et al
    Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25796.
    PubMed     Abstract available

  45. WANG W, Zhang Y, Zhang L, Yang C, et al
    Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study.
    Am J Hematol. 2020;95:E80-E83.

    March 2020
  46. EL CHAER F, Siegel A, Holtzman NG, Bukhari A, et al
    Severe Dysautonomia as a Manifestation of Neurotoxicity after CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25794.

  47. WASTERLID T, Harrysson S, Andersson TM, Ekberg S, et al
    Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Mar 17. doi: 10.1002/ajh.25789.
    PubMed     Abstract available

  48. KAPLAN LD, Maurer MJ, Stock W, Bartlett NL, et al
    Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403.
    Am J Hematol. 2020 Mar 13. doi: 10.1002/ajh.25783.
    PubMed     Abstract available

  49. ZANWAR S, Abeykoon JP, Durot E, King R, et al
    Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia.
    Am J Hematol. 2020;95:274-281.
    PubMed     Abstract available

    February 2020
  50. BELTRAN BE, Castro D, Paredes S, Miranda RN, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2020 Feb 18. doi: 10.1002/ajh.25760.
    PubMed     Abstract available

  51. TIMMERMAN J, Herbaux C, Ribrag V, Zelenetz AD, et al
    Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
    Am J Hematol. 2020 Feb 13. doi: 10.1002/ajh.25757.
    PubMed     Abstract available

  52. FOSS FM, Horwitz SM, Civallero M, Bellei M, et al
    Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.
    Am J Hematol. 2020;95:151-155.
    PubMed     Abstract available

    January 2020
  53. QASRAWI A, Arora R, Ramlal R, Munker R, et al
    Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25725.

    December 2019
  54. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711.
    PubMed     Abstract available

  55. OLSZEWSKI AJ, Butera JN, Reagan JL, Castillo JJ, et al
    Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
    Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25707.
    PubMed     Abstract available

  56. PARSONS K, Leach M, Bain BJ
    Hodgkin lymphoma in a bone marrow aspirate.
    Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25708.

  57. FREEDMAN A, Jacobsen E
    Follicular lymphoma: 2019 update on diagnosis and management.
    Am J Hematol. 2019 Dec 8. doi: 10.1002/ajh.25696.
    PubMed     Abstract available

  58. QIAN L, Soderquist C, Schrank-Hacker A, Strauser H, et al
    Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25694.
    PubMed     Abstract available

    November 2019
  59. RAYCHAUDHURI R, Qualtieri J, Garfall AL
    Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma.
    Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25682.

  60. Abstracts from the 2019 Lymphoma and Myeloma Congress October 23-26, 2019 New York, NY.
    Am J Hematol. 2019;94 Suppl 2:S3-S33.

    October 2019
  61. ABDULLA M, Hollander P, Pandzic T, Mansouri L, et al
    Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Oct 29. doi: 10.1002/ajh.25666.
    PubMed     Abstract available

  62. HERRERA AF, Goy A, Mehta A, Ramchandren R, et al
    Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25659.
    PubMed     Abstract available

    September 2019
  63. MUNIR T, Brown JR, O'Brien S, Barrientos JC, et al
    Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638.
    PubMed     Abstract available

  64. FLINN IW, Cherry MA, Maris MB, Matous JV, et al
    Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia.
    Am J Hematol. 2019 Sep 6. doi: 10.1002/ajh.25634.
    PubMed     Abstract available

  65. HRISTOV AC, Tejasvi T, Wilcox RA
    Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2019;94:1027-1041.
    PubMed     Abstract available

  66. HINTON R, Yebra-Fernandez E, Bain BJ
    Sezary syndrome: The cause of erythema revealed by the blood film.
    Am J Hematol. 2019;94:1042-1043.

  67. PERRY C, Ben Barouch S, Goldschmidt N, Sarid N, et al
    Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Am J Hematol. 2019;94:992-1001.
    PubMed     Abstract available

    August 2019
  68. DEOL A, Uberti J
    Rapid and Sustained Response to CAR T Cell Therapy in Double Hit Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2019 Aug 19. doi: 10.1002/ajh.25621.

  69. HARTMANN S, Plutschow A, Mottok A, Bernd HW, et al
    The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
    Am J Hematol. 2019 Aug 8. doi: 10.1002/ajh.25607.
    PubMed     Abstract available

  70. VARETTONI M, Boveri E, Zibellini S, Tedeschi A, et al
    Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25600.
    PubMed     Abstract available

  71. ZAIN JM
    Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Am J Hematol. 2019;94:929-946.
    PubMed     Abstract available

  72. CHOW VA, Gopal AK, Maloney DG, Turtle CJ, et al
    Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
    Am J Hematol. 2019;94:E209-E213.

    July 2019
  73. BUKHARI A, El Chaer F, Koka R, Singh Z, et al
    Rapid Relapse of Large B-Cell Lymphoma after CD19 Directed CAR-T-Cell Therapy due to CD-19 Antigen Loss.
    Am J Hematol. 2019 Jul 24. doi: 10.1002/ajh.25591.

  74. BAIN BJ
    Pseudoplatelets and apoptosis in Burkitt lymphoma.
    Am J Hematol. 2019 Jul 24. doi: 10.1002/ajh.25586.

  75. ARMAND M, Costopoulos M, Osman J, Tarfi S, et al
    Optimization of CSF biological investigations for CNS lymphoma diagnosis.
    Am J Hematol. 2019 Jul 21. doi: 10.1002/ajh.25578.
    PubMed     Abstract available

  76. RUMI E, Zibellini S, Boveri E, Cavalloni C, et al
    Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
    Am J Hematol. 2019;94:E185-E188.

    June 2019
  77. KHARFAN-DABAJA MA, Jain MD, Aulakh S, Ayala E, et al
    Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
    Am J Hematol. 2019 Jun 18. doi: 10.1002/ajh.25560.

  78. TRACY SI, Larson MC, Feldman AL, Maurer MJ, et al
    The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.
    Am J Hematol. 2019;94:658-666.
    PubMed     Abstract available

    April 2019
  79. ST-PIERRE F, Broski SM, LaPlant BR, Ristow K, et al
    Detection of Extranodal and Spleen Involvement by FDG-PET Imaging Predicts Adverse Survival in Untreated Follicular Lymphoma.
    Am J Hematol. 2019 Apr 21. doi: 10.1002/ajh.25493.
    PubMed     Abstract available

  80. OUSEPH M, Pinkus GS, Dorfman DM
    Pleomorphic mantle cell lymphoma mimicking diffuse large B cell lymphoma in peripheral blood and bone marrow.
    Am J Hematol. 2019 Apr 20. doi: 10.1002/ajh.25491.

  81. JAIN P, Wang M
    Mantle Cell Lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication and management.
    Am J Hematol. 2019 Apr 8. doi: 10.1002/ajh.25487.
    PubMed     Abstract available

  82. ISIDORI A, Loscocco F, Guiducci B, Visani G, et al
    Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.
    Am J Hematol. 2019;94:E104-E105.

  83. CHANTEPIE S, Yakoub-Agha I, Damaj G
    Be ever cautious until the truth is proven.
    Am J Hematol. 2019;94:E106.

  84. SMITH SD, Reddy P, Sokolova A, Chow VA, et al
    Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
    Am J Hematol. 2019;94:E117-E116.

  85. HAMLIN PA, Flinn IW, Wagner-Johnston N, Burger JA, et al
    Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    Am J Hematol. 2019;94:E90-E93.

    March 2019
  86. STUVER RN, Khan N, Schwartz M, Acosta M, et al
    Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry.
    Am J Hematol. 2019 Mar 21. doi: 10.1002/ajh.25463.
    PubMed     Abstract available

  87. LIU Y, Barta SK
    Diffuse Large B cell Lymphoma: 2019 update on diagnosis, risk-stratification and treatment.
    Am J Hematol. 2019 Mar 11. doi: 10.1002/ajh.25460.
    PubMed     Abstract available

  88. MAURA F, Agnelli L, Leongamornlert D, Bolli N, et al
    Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma.
    Am J Hematol. 2019 Mar 4. doi: 10.1002/ajh.25450.
    PubMed     Abstract available

  89. FURUTANI E, Newburger PE, Shimamura A
    Neutropenia in the age of genetic testing: Advances and challenges.
    Am J Hematol. 2019;94:384-393.
    PubMed     Abstract available

    February 2019
  90. WANG Y, Habermann TM, Wang SS, Maurer MJ, et al
    Host Genetic Variation in the TNF and NF-kB Pathways and Overall Survival in Mantle Cell Lymphoma: A Discovery and Replication Study.
    Am J Hematol. 2019 Feb 27. doi: 10.1002/ajh.25451.

  91. STRATI P, Lee ST, Teegavarupu P, Karri A, et al
    Frontline Antibiotic Therapy for Early Stage Helicobacter Pylori Negative Gastric MALT Lymphoma.
    Am J Hematol. 2019 Feb 20. doi: 10.1002/ajh.25447.

  92. ALDERUCCIO JP, Zhao W, Desai A, Ramdial J, et al
    Short Survival and Frequent Transformation in Extranodal Marginal Zone Lymphoma with Multiple Mucosal Sites Presentation.
    Am J Hematol. 2019 Feb 19. doi: 10.1002/ajh.25446.
    PubMed     Abstract available

  93. SAWAYAMA Y, Itonaga H, Fukushima T, Nakano N, et al
    Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
    Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25438.

  94. ARORA N, Eule C, Gupta A, Li HC, et al
    Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience.
    Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25432.

  95. LUCIJANIC M, Prka Z, Jaksic O, Mitrovic Z, et al
    Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality.
    Am J Hematol. 2019;94:E42-E43.

    January 2019
  96. HONG H, Huang H, Fang X, Wang Z, et al
    A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Am J Hematol. 2019 Jan 28. doi: 10.1002/ajh.25426.

  97. DE LA FUENTE MI, Alderuccio JP, Reis IM, Omuro A, et al
    Bilateral Radiation Therapy followed by Methotrexate-based Chemotherapy for Primary Vitreoretinal Lymphoma.
    Am J Hematol. 2019 Jan 21. doi: 10.1002/ajh.25414.
    PubMed     Abstract available

    December 2018
  98. CASTELLINO A, Pulido JS, Johnston PB, Ristow KM, et al
    Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
    Am J Hematol. 2018 Dec 5. doi: 10.1002/ajh.25350.
    PubMed     Abstract available

    November 2018
  99. MACKRIDES N, Chapman J, Larson MC, Ramos JC, et al
    Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25357.

  100. KLENER P, Salek D, Pytlik R, Mocikova H, et al
    Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25362.
    PubMed     Abstract available

    October 2018
  101. WONG WJ, Ruhangaza D, Manirakiza A, Omondi J, et al
    Concomitant Classic Hodgkin Lymphoma and Schistosomiasis.
    Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25316.

    September 2018
  102. POPHALI PA, Ip A, Larson MC, Rosenthal AC, et al
    The Association of Physical Activity Before and After Lymphoma Diagnosis with Survival Outcomes.
    Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25288.
    PubMed     Abstract available

  103. TISI MC, Paolini R, Piazza F, Ravelli E, et al
    Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Am J Hematol. 2018 Sep 5. doi: 10.1002/ajh.25278.

    August 2018
  104. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Abstract available

  105. BAIN BJ, Branislav C
    Monocyte adhesion with platelet satellitism and phagocytosis in Hodgkin lymphoma.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25241.
    PubMed     Abstract available

    July 2018
  106. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Abstract available

  107. SIOW W, Burton K, Eagleton H, Campbell C, et al
    Transformation of follicular lymphoma.
    Am J Hematol. 2018 Jul 24. doi: 10.1002/ajh.25195.

  108. HILAL T, Wang Z, Almader-Douglas D, Rosenthal A, et al
    Rituximab Maintenance Therapy for Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25226.
    PubMed     Abstract available

  109. FLINN IW, Patel M, Oki Y, Horwitz S, et al
    Duvelisib, an Oral Dual PI3K-delta, gamma Inhibitor, Shows Clinical Activity in Indolent Non-Hodgkin Lymphoma in a Phase 1 Study.
    Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25228.
    PubMed     Abstract available

  110. CASTILLO JJ, Beltran BE, Miranda RN, Young KH, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2018;93:953-962.
    PubMed     Abstract available

    June 2018
  111. BAIN BJ
    Diagnosis of follicular lymphoma from the peripheral blood.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25158.

  112. ROSSI C, Gilhodes J, Maerevoet M, Herbaux C, et al
    Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
    PubMed     Abstract available

    May 2018
  113. EKBERG S, Jerkeman M, Andersson PO, Enblad G, et al
    Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25147.
    PubMed     Abstract available

  114. PATEL S, Li Y, Berchuck JE, Cunningham J, et al
    Did you 'miss' me? A subtle case of intravascular large B-cell lymphoma.
    Am J Hematol. 2018 May 13. doi: 10.1002/ajh.25132.

  115. ANSELL SM
    Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2018;93:704-715.
    PubMed     Abstract available

    April 2018
  116. SIEGELE BJ, Nardi V
    Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
    Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
    PubMed     Abstract available

  117. PARDAL E, Diez Baeza E, Salas Q, Garcia T, et al
    Which very elderly diffuse large B-cell lymphoma patients can benefit from curative treatment? A multicenter, retrospective analysis by the Spanish GELTAMO group.
    Am J Hematol. 2018 Apr 15. doi: 10.1002/ajh.25107.
    PubMed     Abstract available

    February 2018
  118. CHANTEPIE SP, Garciaz S, Tchernonog E, Peyrade F, et al
    Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
    Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25077.
    PubMed     Abstract available

  119. CARBONE A, Gloghini A
    Current and potential use of pathological targets in the treatment of Hodgkin lymphoma.
    Am J Hematol. 2018 Feb 2. doi: 10.1002/ajh.25054.

    Follicular lymphoma: 2018 update on diagnosis and management.
    Am J Hematol. 2018;93:296-305.
    PubMed     Abstract available

    January 2018
  121. OLSZEWSKI AJ, Reagan JL, Castillo JJ
    Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Am J Hematol. 2018;93:E1-E3.

    December 2017
  122. PERSKY DO, Li H, Rimsza LM, Barr PM, et al
    A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.
    Am J Hematol. 2017 Dec 20. doi: 10.1002/ajh.25010.
    PubMed     Abstract available

  123. BOONSTRA PS, Polk A, Brown N, Hristov AC, et al
    A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
    Am J Hematol. 2017;92:1287-1294.
    PubMed     Abstract available

    November 2017
  124. RIBES D, El Hachem H, Oberic L, Vergez F, et al
    Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Am J Hematol. 2017 Nov 23. doi: 10.1002/ajh.24984.
    PubMed     Abstract available

  125. XAVIER AC, Epperla N, Taub JW, Costa LJ, et al
    Excess Mortality Among Ten-Year Survivors of Classical Hodgkin Lymphoma in Adolescents and Young Adults.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24964.
    PubMed     Abstract available

    October 2017
  126. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Abstract available

  127. AKHTAR S, Montoto S, Boumendil A, Finel H, et al
    High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation (EBMT)-Lymphoma Working Party.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24927.
    PubMed     Abstract available

  128. WILCOX RA
    Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:1085-1102.
    PubMed     Abstract available

  129. LOMBARDI A, Croci GA, Brazzelli V, Vecchia M, et al
    Cutaneous septic emboli from Candida glabrata in a haematological patient.
    Am J Hematol. 2017;92:1111-1112.

    September 2017
  130. BELETE H, Burns LJ, Shanley R, Nayar M, et al
    Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.
    Am J Hematol. 2017;92:E529-E533.
    PubMed     Abstract available

  131. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.

    August 2017
  132. VOSE JM
    Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Am J Hematol. 2017;92:806-813.
    PubMed     Abstract available

    July 2017
  133. MALECEK MK, Petrich AM, Rozell S, Chu B, et al
    Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.
    Am J Hematol. 2017 Jul 18. doi: 10.1002/ajh.24864.
    PubMed     Abstract available

  134. WITZIG TE, Zinzani PL, Habermann TM, Tuscano JM, et al
    Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24854.
    PubMed     Abstract available

    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol. 2017;92:706-715.
    PubMed     Abstract available

    June 2017
  136. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.

  137. WITZIG TE, Johnston PB, LaPlant BR, Kurtin PJ, et al
    Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkin Lymphoma: Results of a study of the Mayo Clinic Cancer Research Consortium (MCCRC) MC0
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24824.
    PubMed     Abstract available

  138. SAYGIN C, Jia X, Hill B, Dean R, et al
    Impact of Comorbidities on Outcomes of Elderly Patients with Diffuse Large B-cell Lymphoma.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24819.
    PubMed     Abstract available

  139. LANZA F, Saraceni F, Pezzi A, Martino M, et al
    A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24817.

    May 2017
  140. HELBER MJ, Moore JE, Williams AM, Meacham PJ, et al
    Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.
    Am J Hematol. 2017 May 24. doi: 10.1002/ajh.24795.

  141. BAIR SM, Strelec L, Nagle SJ, Nasta SD, et al
    Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
    Am J Hematol. 2017 May 16. doi: 10.1002/ajh.24792.
    PubMed     Abstract available

    April 2017
  142. BINDER M, O'Byrne MM, Maurer MJ, Ansell S, et al
    Associations between Elevated Pre-treatment Serum Cytokines and Peripheral Blood Cellular Markers of Immunosuppression in Patients with Lymphoma.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24758.
    PubMed     Abstract available

  143. HANSEN JW, Garde C, Asmar F, Tholstrup D, et al
    Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Am J Hematol. 2017 Apr 5. doi: 10.1002/ajh.24751.
    PubMed     Abstract available

    March 2017
  144. MAJOR A, Pan Z, Kamdar M
    Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733.

    January 2017
  145. RIZZO D, Viailly PJ, Mareschal S, Bohers E, et al
    Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.
    Am J Hematol. 2017;92:68-76.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.